CSIMarket Company Name, Ticker, Competitors, else..
 
Zynerba Pharmaceuticals Inc   (NASDAQ: ZYNE)
Other Ticker:  
 
 
Price: $1.3000 $0.03 2.362%
Day's High: $1.34 Week Perf: 7.44 %
Day's Low: $ 1.26 30 Day Perf:
Volume (M): 838 52 Wk High: $ 0.00
Volume (M$): $ 1,089 52 Wk Avg: $0.00
Open: $1.26 52 Wk Low: $0.00



 Market Capitalization (Millions $) 65
 Shares Outstanding (Millions) 50
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -38
 Cash Flow (TTM) (Millions $) -27
 Capital Exp. (TTM) (Millions $) 0

Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc is a biopharmaceutical company that specializes in developing and commercializing transdermal cannabinoid therapies for various medical conditions. The company focuses on developing innovative treatments for patients who have limited options or who may not have responded well to other therapies. Zynerba's proprietary technology allows for the delivery of cannabinoids through the skin, offering advantages such as precise dosing and continuous drug delivery. The company's lead product candidate is Zygel, which is being developed for the treatment of Fragile X syndrome, Autism spectrum disorder, 22q11.2 Deletion Syndrome, and other neuropsychiatric disorders. Zynerba Pharmaceuticals aims to improve the lives of patients by providing effective, convenient, and safe cannabinoid-based therapies.


   Company Address: 80 W. Lancaster Avenue Devon 19333 PA
   Company Phone Number: 581-7505   Stock Exchange / Ticker: NASDAQ ZYNE


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AKBA        10.7% 
BMRN   -8.15%    
HZNP        0.46% 
IRWD   -2.92%    
SRPT   -0.36%    
VRTX        2.09% 
• View Complete Report
   



Shares

Zynerba Pharmaceuticals Calls on Investors to Seize Unique Opportunity in Partnership with Harmony Biosciences Tender Offer

Published Wed, Oct 4 2023 8:05 PM UTC

Zynerba Pharmaceuticals Urges Stockholders to Tender Shares in Harmony Biosciences Tender Offer
DEVON, Pa., Oct. 04, 2023 - Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), a leading provider of innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, is urging all stockholders, including individual investors, to promptly...
Shares

Zynerba Pharmaceuticals Encourages Stockholders to Evaluate Impending Tender Offer by Harmony Biosciences

Published Fri, Sep 29 2023 1:00 PM UTC


Introduction
DEVON, Pa., Sept. 29, 2023 - Zynerba Pharmaceuticals Inc. (Nasdaq: ZYNE), a leading innovator in pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, has released a letter to its stockholders addressing the pending tender offer from Harmony Biosciences Holdings, Inc. In light of this development, it is cruci...
Zynerba Pharmaceuticals Inc

Existing Outlays at Zynerba Pharmaceuticals Inc Experience Rapid Growth in the Financial Period Ending June 30, 2023


Date: October 18, 2023
Investors closely observe Zynerba Pharmaceuticals Inc (ZYNE) as the Major Pharmaceutical Preparations company reports its financial performance for the period ending June 30, 2023. While no significant adjustments were expected during the quarter, shareholders are paying close attention to the company's operating deficit, which has significantly increased in recent quarters.
During the quarterly earnings cycle of April to June 2023, Zynerba Pharmaceuticals' operating deficit stood at $-11.136207 million, compared to $-9.16877 million in the previous year's second quarter, indicating a concerning trend. The mounting deficit raises questions about the company's ability to generate revenue, prompting investors to closely monitor the upcoming financial results.
Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals Inc Experiences Rising Expenses and Double-Digit Losses in Q1 2023

Zynerba Pharmaceuticals Inc, a healthcare sector-based company, has recorded a cumulative net loss of $-37 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on investment (ROI) of -74.89%. Compared to other companies in the same sector, Zynerba Pharmaceuticals Inc's ROI is lower, with 620 other companies having a higher ROI. However, Zynerba Pharmaceuticals' overall ROI ranking has progressed - from 4121 in the fourth quarter of 2022 to 3372 in the first quarter of 2023.
The Major Pharmaceutical Preparations industry contributors are focusing on Zynerba Pharmaceuticals' first-quarter earnings. As of now, the company has not cited any top-line for the respective January to March 31, 2023 quarter, resulting in an operating shortfall of $-10.471175 million. In the upcoming span of the corporation, the shareholders expect further revenue sources to come as soon as feasible. However, they are less concerned about the recent productivity improvement reported. Unsurprisingly, the expanding firm has reported a shortfall of $-10.114 million, compared to $-8.491 million in the same time-frame a year ago.









Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com